3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumors
1
Interventions
pembrolizumab
4
Injections
3
Nivolumab
2
Docetaxel
2
taxane
1
pazopanib
1
palbociclib
1
lenvatinib
1
demplatin pegraglumer
1
cobimetinib
1
birinapant
1
Topotecan
1
Tablets
1
ODM-207
1
Infusions, Intravenous
1
HLA-A*24:02 antigen
1
Gemcitabine
1
E-3810
1
CB-839
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Solid Tumors
×
ODM-207
×
Clear all
NCT03035591
2019-10-15
BETIDES
Orion Corporation, Orion Pharma
Phase 1/2
Completed
36 enrolled